IBIO

iBioA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-22

Current thesis

Regulatory clearance, potential IBIO-600 clinical initiation, positive albeit preliminary IBIO-610 NHP data, and reported runway into Q4 fiscal 2028 provide a credible path to sentiment improvement. The company also expanded into PH-HFpEF [#SEC-8K-2026-05-12].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite.

What can break

Analyst coverage, recent-news coverage, and social-sentiment data are unavailable, limiting external validation.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $1.55 · Bull $2.10 · Bear $0.80

Data freshness

Prices

As of 2026-07-22

Fundamentals

As of 2026-07-22 • Vendor: Data Vendor v1

Scores

As of 2026-07-22 • Model: HYBRID_IC_RP

AI Memo

As of 2026-07-22 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-22

Supporting evidence

What

Grade A · Constructive

Confidence Medium · Net Neutral

Target $5.53

Why

Momentum96 · Δ7d -

Value59 · Δ7d -0.2

Sentiment55 · Δ7d -

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.2

Δ21d

+17.3

Sentiment

34% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade A. Momentum 95.6 / Value 58.6 / Sentiment 55.3

Fundamentals (TTM)

As of 2026-07-22

Market Cap

$68.56M

Beta

1.26

Shares Out

49.68M

P/E (TTM) · Derived

-0.8

P/S (TTM)

84.55

P/FCF (TTM) · Derived

-2.77

Rev YoY

-100.0%

EPS YoY

-86.9%

Gross Margin

-255.0%

Op Margin

-4089.4%

Net Debt

-$5.07M

Current Ratio

11.88

As of 2026-07-22 • Updated nightlySource: Internal modelMethodology